Cardica improved anastomosis technology:
This article was originally published in Clinica
Executive Summary
Cardica has received US FDA 510(k) clearance to market a new version of its automated anastomosis technology that it claims will give surgeons improved manoeuvrability when attaching blood vessels and grafts during coronary artery bypass graft (CABG) procedures. The device, called C-Port Flex A, is also expected to bring "the possibility of performing truly minimally invasive cardiac surgery" several steps closer, said the Redwood City, California firm. It features several modifications to Cardica's previous C-Port xA product: It has a flexible, rather than rigid, shaft; is effective in creating compliant anastomoses in vessels as small as one millimetre in diameter; and can be used in either on- or off-pump CABG procedures. Importantly, the device can be positioned to create a secure connection in the most difficult to reach areas of the heart, the firm added.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.